I personally have no idea why some give Akki such a hard time just because his/her views are contrary to your own. In fact Akki has been correct about a number of things over the years and has never beat his/her chest over it. I use Akki's comments as a way to challenge my own thoughts on the company.
I still remember Akki correctly pointed out during Serepta's CR that their comments regarding partnerships and acquisitions was a generic paragraph they always include in all their previous CRs but received backlash over it. Unpopular opinion but Akki is one of the few posters I actually pay attention to. At least he/she doesn't flood their comments with $ $ $ $ symbols and post outrageous share price predictions.
Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-64
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.5¢ | $18.25K | 237.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18038 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
-0.001 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.0¢ | 7.5¢ | 59548 | ||
| Last updated 15.20pm 10/05/2024 ? | |||||
| PER (ASX) Chart |